Log in to save to my catalogue

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ae82624b40e944a5925f8f3c70ded9b7

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that i...

Alternative Titles

Full title

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ae82624b40e944a5925f8f3c70ded9b7

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ae82624b40e944a5925f8f3c70ded9b7

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-024-46536-w

How to access this item